glp 1 agonists for alcohol use disorder IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance disorders: An emerging pharmacotherapeutic target GLP-1 Agonists for Alcohol Use

According to Drucker the findings, published in December 2023, provided the first demonstration of 'a GLP-1-brain-immune axis that controls inflammation across the body independent of weight loss, even in peripheral organs devoid of GLP1 receptors.' Drucker's team has not yet identified which particular brain cells interact with GLP-1 (AAAS)

If the phase 2b trial goes well, its possible the company could trial the combination of bimagrumab and tirzepatide or another one of the GLP-1 agonists in its pipeline

Sources Endocrine Society Consuming more protein may protect patients taking an anti-obesity drug from muscle loss endocrine.org University of Utah Health Want to Lose Weight

doi: 10.1056/NEJMoa2028395 194 FangXDuZDuanCZhanSWangTZhuMet al

Liraglutide inhibits the proliferation and promotes the apoptosis of MCF-7 human breast cancer cells through downregulation of microRNA-27a expression